You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
Taiwan-based Personal Genomics, which is developing a new single-molecule sequencing platform, has previously sued PacBio for patent infringement in the US.
The sequencing firm reported total revenues of $15.6 million, with instrument revenue negatively impacted by shutdowns precipitated by COVID-19.
The San Diego-based genomics technology firm recognized Q1 revenues of $859 million, compared to $846 million in Q1 2019.
Among other projects, PacBio is working with LabCorp to sequence a large number of SARS-CoV-2 genomes from de-identified positive samples.
GenomeWeb asked a number of prominent researchers in the field via email about their top picks for notable developments or achievements in genomics during the 2010s.
The Delaware jury said Oxford Nanopore had infringed three patents, but also found that they were invalid, mostly because they were not enabled.
Of the 32 firms included in the GW Index, 27 saw their stock prices drop while only five saw gains. Yet, the GW Index outperformed the Dow and Nasdaq.
PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.